Response to Infliximab in Crohn’s Disease: Genetic Analysis Supporting Expression Profile

Table 5

Haplotype frequencies and comparison between colonic Crohn’s patients with L2 and L3 location, responders and nonresponders to infliximab therapy, in the chromosomal regions including: (a) S100A9 and S100A8 genes (rs11205276, rs3014866, rs724781, and rs3006488); (b) G0S2 gene (rs4844486, rs1473683); (c) TNFAIP6 gene (rs11677200, rs2342910, rs3755480, and rs10432475); and (d) IL11 gene (rs1126760, rs1042506).

(a)

Haplotype	Responders (%)	Nonresponders (%)	value
GCGA	25.1	21.5	0.56
GCCA	22.7	35.9	0.025
GTCA	20.7	11.6	0.10
CTCA	8.8	10.8	0.52
GTGA	5.2	1.8	0.33
GCCG	4.1	7.2	0.33
CCCA	4.2	3.5	1.00
GTGG	2.4	1.2	1.00
GTCG	2.1	2.3	1.00
CCGA	1.6	1	1.00
GCGG	1.2	1.6	0.58
CTGA	1.1	0.6	0.52
CCCG	0.8	1.1	0.44

(b)

Haplotype	Responders (%)	Nonresponders (%)	value
CG	72.1	71.7	0.94
AG	27.1	23.2	0.54
AT	0.8	5.2	0.036

(c)

Haplotype	Responders (%)	Nonresponders (%)	value
CAGA	44.5	44.1	0.87
TAGA	17.2	19.4	0.61
TTGA	15.7	16.6	0.86
TAAA	11.9	8.3	0.43
TTGG	10.3	11.6	0.74

(d)

Haplotype	Responders (%)	Nonresponders (%)	value
TT	76	62.8	0.040
CT	11.5	27.2	0.0012
CG	11.7	6.1	0.17
TG	0.8	3.9	0.12